General Catalyst Investment Values BrightInsight at $750 Million
- Startup builds digital tools for drugmakers, medical devices
- Investors have put $26 billion into digital health ventures
This article is for subscribers only.
BrightInsight, a health technology company that helps drug and device makers build digital tools for patients and clinicians, raised $101 million in venture capital from investors including General Catalyst.
The investment values California-based BrightInsight at about $750 million, according to a person close to the company who asked not to be identified discussing private information. The latest round brings the company’s total equity funding to $166 million.